Massachusetts General Hospital Cancer Center

Boston, Massachusetts
Director, Massachusetts General Hospital Cancer Center
Professor of Oncology,  Harvard Medical School

Research

Dr. Haber is a renowned leader on genetic abnormalities of cancer – from inherited mutations (with familial predisposition) to mutations that are acquired by tumors themselves. With NFCR funding since 2000, his research aims to guide targeted drug therapies.

His current NFCR-supported work focuses on circulating tumor cells (CTCs) that are shed from a primary tumor and metastatic sites and then enter the bloodstream. CTCs are rare in numbers and only a few are lurking between the millions of healthy cells in a standard blood sample.

He and his collaborators developed the CTC-iChip—an advanced micro-engineered device that captures the few CTCs present in a patient’s blood sample. Their research has developed methods to culture viable CTCs to increase their numbers, conduct genetic testing and other tests, which results can dramatically improve treatment and diagnosis for patients with many types of cancers.

The CTC-iChip is already used in some clinical research laboratories and will be submitted for FDA-approval. Oncologists can then use the blood test to obtain results to make timely life-saving treatment decisions for their patients.

CTCs may be present in the bloodstream early in the origin cancer and can lodge within distant organs and remain dormant (resting state), only to be reactivated after many years, giving rise to metastatic cancer. Utilizing the powerful CRISPR gene-editing tool (whose discoverers were awarded a Nobel Prize in 2020), Dr. Haber is identifying the genes in models of metastatic breast cancer that control CTCs’ ability to enter into dormancy and then reactivate. His team has identified one protein that dramatically enhances the metastatic propensity of CTCs. Every single gene in the entire genome is being interrogated in these CRISPR screens.

Dr. Haber’s groundbreaking research on metastatic breast cancer could ultimately develop treatments that target the genes and suppress reactivation of resting cancer cells. Thousands of patients would be given hope that the return of their cancer many years later could be prevented.

Bio

Daniel A. Haber, M.D., Ph.D., is the Director of the Massachusetts General Hospital (MGH) Cancer Center and a professor of oncology at Harvard Medical School. He received his Bachelor and Master degrees from the Massachusetts Institute of Technology (MIT), and received a M.D. and Ph.D. from Stanford University School of Medicine. Following his schooling, Dr. Haber conducted his postdoctoral training at MIT and joined the Harvard Medical School faculty in 1991 as an assistant professor.

Dr. Haber is most interested in the area of cancer genomics, including the study of circulating tumor cells, the Wilms tumor and genetic predisposition to breast cancer.

In addition to his award with NFCR, Dr. Haber is an elected member of the National Academy of Medicine, the National Academy of Science, a fellow of the American Academy of Arts and Sciences, on the Board of Directors for the American Association for Cancer Research and a member of the Association of American Physicians and the American Society for Clinical Investigation. He is also on the editorial boards of Cell, Cancer Cell, Molecular Cancer Research and Cancer Discovery and has served as genetics editor for the New England Journal of Medicine.

Dr. Haber has been honored with numerous awards such as the inaugural National Foundation for Cancer Research (NFCR) and the American Association for Cancer Research (AACR) Professorship in Basic Cancer Research, a MERIT Award from the National Cancer Institute, the Emil Freireich Award from MD Anderson Cancer Center, Stand Up to Cancer Dream Team Award, a Dream Team Award from the Prostate Cancer Foundation, the Sternlicht Award from Case Western Reserve and the Hinda Rosenthal Award for Translational Research from the AACR.

Related Content

Pancreatic Cancer: Warnings and Wellness

NFCR Chief Medical Officer Shares His Expertise for Improved Pancreatic Cancer Awareness The National Foundation for Cancer Research (NFCR)’s Dr. Brian Leyland-Jones contributed to the popular online platform Eat This, Not That!’s feature in efforts to spread awareness of one of the most deadly and difficult to detect cancers: 11 Warning Signs of Pancreatic Cancer. Dr. Leyland-Jones’ career spans decades, and has led him to become an authority within the pancreatic cancer-fighting community. Dr. Leyland Jones serves as Board Member and Chief Medical Officer for NFCR, offering his extensive expertise to NFCR’s fundraising missions. Boasting over 100 million readers, Eat This, Not That! publishes expert- and research-backed tips on food, nutrition, and health. Dr. Leyland-Jones’ tips on pancreatic cancer awareness help strengthen the deep catalogue of recipes, diet recommendations, and general wellness tips on the popular online platform. Warning Signs Early detection is crucial for early intervention with pancreatic cancer. The disease has an overall five-year survival rate of just 9% and is likely to rise to become the second leading cause of cancer-related deaths in the U.S. by the year 2030. These facts, coupled with pancreatic cancer’s significant reputation as one of the silent killers, showcase the importance of knowing these 11 warning signs: Blood Clots Ascites Jaundice Sudden Weight Loss Upper Abdominal Pain Depression and Anxiety (Before Diagnosis) Nausea and Vomiting Diabetes Pale Feces and Dark Urine Enlarged Gallbladder or Liver Unexplainable Fatigue Outside of these symptoms, Dr. Leyland-Jones emphasizes the importance of keeping up-to-date on your yearly physicals, stating, “It is very difficult to detect early. For yearly physicals, some people also get PET scans and CT scans. However, the progression is so fast, these kinds of scans would need to be done every six months.” With approximately 60,000 new cases per year, pancreatic cancer will continue to be a significant concern. Know these warning signs and keep up with day-to-day wellness and yearly physicals in order to stay on top of your health!   Did you know that November is Pancreatic Cancer Awareness Month? Subscribe to NFCR social media channels to stay up to date on the latest developments in the fight against pancreatic cancer. You can also visit our donation page to join in our fundraising efforts! Additional Reads You May Enjoy: Thunder God Vine: A Powerful Discovery for Pancreatic Cancer Patients 5 Tips for Eating Healthy While Traveling Coping With Cancer—It’s Different for Everyone Receive our monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips and more. Sign up here. 

Thunder God Vine: A Powerful Discovery for Pancreatic Cancer Patients

With a name as powerful as Thunder God Vine comes great responsibility – and National Foundation for Cancer Research (NFCR)-funded researcher Dr. Daniel D. Von Hoff has proven that this medicinal plant is up for the challenge.  Dr. Von Hoff is considered one of the nation’s leading authorities on pancreatic cancer.  He and his team began exploring how thunder god vine — an herb used in China for centuries to treat joint pain, swelling, and fever — could be used for cancer patients. The team was overcome with excitement as they discovered a particular compound in this miracle herb can kill cancer cells and potentially improve clinical outcomes for patients with pancreatic cancer. Pancreatic cancer is the ninth and tenth most commonly diagnosed cancer in women and men, respectively, in the United States. It is the fourth deadliest cancer and is one of the few cancers for which survival has not improved substantially in over 40 years. An estimated 57,600 new cases of pancreatic cancer will be diagnosed in the United States this year, with 47,050 deaths expected to result from the diagnosis. With little to no groundbreaking discoveries or treatment, pancreatic cancer is expected to become the second leading cause of cancer-related deaths in the United States by 2030. The key ingredient of the thunder god vine is called triptolide. Triptolide makes up a molecule called Minnelide, which appears to attack pancreatic cancer cells. It also attacks the tumor’s stroma or outer layer that shields it from the body’s immune system. This allows Minnelide to disrupt ‘super-enhancers,’ strings of DNA that aid the growth and survival of pancreatic cancer cells. The team found that disrupting these super-enhancers attacks the cancer cells and the stroma, which helps accelerate cancer cell death. Thunder god vine is commonly found in China and has been used in traditional Chinese medicine for hundreds of years. The approaches that make up traditional Chinese medicine, including acupuncture, tai chi, and herbal products, have been the subjects of many clinical studies and scientific reviews. Researchers have concluded that traditional Chinese medicine may help improve quality of life and certain pain conditions, and it is becoming more and more prevalent in western medicine practices. Today, for example, thunder god vine is used for rheumatoid arthritis, multiple sclerosis, Crohn’s disease, lupus, psoriasis, fever, amongst other conditions.  This new approach using an old method may provide means for effective treatment options for pancreatic cancer patients, a glimmer of hope that health professionals and patients have long-awaited. To learn more about groundbreaking research undertaken by NFCR-funded researchers, visit our scientist page. Additional Reads You May Enjoy: Controlling the Uncontrollable: HER2 Breast Cancer Propelling the Fight Against Pancreatic Cancer Ancient Wisdom, Modern Cure Stay connected with the cancer community! Receive NFCR’s monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips, and more. Sign up here.

Life Happens Quickly: Aly’s Story

As we grow older, we learn to understand that life happens quickly. Aly Newel learned just how quickly things could happen when she was screened for, diagnosed with, and received breast cancer treatment, all within 22 days. After losing her mother to breast cancer, Aly devotedly underwent her mammograms as recommended since turning 30 years old. In early 2016, she suddenly realized that she had missed her annual appointment by nearly six months. She quickly made an appointment, not thinking too much about the lapse as everything felt normal.  “My general practitioner told me that the test had detected abnormal cells in my left breast and that she was referring me to a surgeon,” Aly shared. “It wasn’t more than a couple of days before I was with the breast surgeon in absolute shock at how quickly this had happened. With everything that happened with my mom, I was scared.” Aly soon received the biopsy results that quickly filled her with dread as she learned she had breast cancer. Luckily, the ductal carcinoma in-situ was in the early stages and completely treatable.  “I was stunned,” Aly reflected. “How can he have just told me that I have breast cancer, yet it is curable? Honestly, it took me a while to get my head around that.” Before she could fully wrap her head around the news, Aly had a hook wire insertion and lumpectomy.  “These operations sound really scary, but they aren’t at all,” Aly said. “The surgeon came to see me after the operation and told me that everything had gone really well and that the cancer was gone.” Aly felt amazing – pain-free and thrilled to be rid of the nasty disease. She had zero pain and only a little scar on her left breast for which to remember the whirlwind experience. With just a single dose of radiotherapy, she closed this scary yet short chapter.  “I would like to share my story because as a mother of two daughters, I feel that it’s really important to promote early detection by encouraging women to become familiar with the regular feel of their breasts and participate in the screening programs that they are eligible for,” Aly stated. “I also think it’s important for people to realize that being diagnosed with breast cancer doesn’t necessarily have a bad outcome if it’s found early.” Life happens quickly, and sometimes it is easy to forget the small steps that make a big difference – like scheduling regular mammograms. Luckily, the National Foundation for Cancer Research (NFCR) has you covered. Follow NFCR on social media or check out our Cancer-Fighting Lifestyle Tips to keep you and your loved ones safe.  Additional Reads You May Enjoy: Let’s talk about Mammograms with Dr. Alexia Matheson Don’t Delay: Skipping One Mammogram Can Significantly Increase Risk of Death from Breast Cancer Mastectomy and Breast Reconstruction: What Breast Cancer Patients Should Know   Stay connected with the cancer community! Receive NFCR’s monthly e-newsletter and blogs featuring stories of inspiration, support resources, cancer prevention tips, and more. Sign up here.